DoD Peer Reviewed Orthopaedic Clinical Consortium Award | Apply Online

FAQs: DoD Peer Reviewed Orthopaedic Clinical Consortium Award (PRORP CCA)

What is the PRORP Clinical Consortium Award (CCA)?

The PRORP CCA is a Department of Defense (DoD) research funding opportunity designed to support large, multi-site clinical studies focused on improving outcomes for severe musculoskeletal injuries that are common in military combat.

What is the main goal of this award?

The central goal is to generate stronger, more reliable clinical evidence for complex combat-related orthopaedic trauma by coordinating across many sites, pooling patients, and running studies that are large enough to answer high-impact clinical questions.

Why does the program emphasize multi-site studies?

A core theme is statistical power. Multi-site enrollment and pooled patient populations can produce more robust findings than single-center studies, particularly for complex injuries where any one site may not see enough patients to support a definitive trial.

When was this program first offered?

The PRORP CCA was first offered in fiscal year (FY) 2009.

What types of injuries or clinical areas does it focus on?

The focus is on severe musculoskeletal injuries, especially combat-relevant orthopaedic trauma and major limb and musculoskeletal injuries typical of military combat environments.

What kind of studies is the award intended to support?

It is intended to support large, multi-site clinical studies conducted by an integrated consortium capable of coordinating patient enrollment, clinical protocols, data collection, and analysis across participating sites.

What does the DoD mean by building a "true clinical consortium"?

The award is structured to create an integrated network linking military and civilian capabilities. It is not intended to be a loose collaboration; it is meant to coordinate operations across sites so the consortium functions as a unified clinical research enterprise.

How are military and civilian organizations expected to participate?

On the military side, the consortium leverages orthopaedic trauma patient populations and combat-relevant experience at designated military treatment facilities (MTFs) referenced in the full announcement. On the civilian side, it incorporates highly qualified orthopaedic trauma departments and strong research teams at leading institutions.

What outcomes are studies expected to measure?

The program emphasizes longitudinal clinical outcomes tied to definitive care. Studies are expected to follow patients over time and evaluate real-world results of treatment, including surgical reconstruction, clinical rehabilitation, and the ability to return to optimal function.

Is the program more focused on practical outcomes or short-term metrics?

It is oriented toward practical patient outcomes over time rather than short-term metrics alone, with the intent that results can inform treatment decisions, recovery pathways, and standards of care.

What is meant by "definitive care" in this context?

Within the description provided, definitive care includes the treatments and recovery processes intended to restore function, such as surgical reconstruction and clinical rehabilitation, and assessing patients ability to return to optimal function.

What is the expected impact beyond publications?

The DoD expects the award to leave behind durable infrastructure that can support continuing clinical studies on combat-relevant musculoskeletal injuries beyond the initial funding period, not just publications.

What kinds of tangible products are expected from the consortium?

Examples listed include clinical information that changes decision-making, practice guidelines, validated techniques, or even devices, with the overarching goal of improving current clinical practice or validating approaches already being used.

What is the bottom-line measure of success for this award?

Better outcomes for injured service members is identified as the bottom-line measure.

What is the Funding Opportunity Number for this award?

The Funding Opportunity Number is W81XWH-09-PRORP-CCA.

What type of funding mechanism is used?

The opportunity was offered as a discretionary cooperative agreement through the Department of the Army and administered by USAMRAA.

What does a cooperative agreement imply for project execution?

Based on the description provided, the cooperative agreement mechanism typically signals substantial federal involvement or coordination during project execution, which aligns with a consortium model and multi-site clinical trial focus.

How many awards were anticipated?

The program anticipated making a single award.

What was the estimated total funding level?

The estimated total funding level was $46,500,000.

Is cost sharing or matching required?

No cost sharing or matching requirement was stated for this opportunity.

Who was eligible to apply?

Eligibility was described as unrestricted, meaning a wide range of organizations could apply, subject to any additional eligibility notes contained in the full announcement.

When was the opportunity posted and when did it close?

The posted and created date was October 1, 2009. The closing date was January 11, 2010.

Is this opportunity still open?

No. The opportunity is described as archived, with an archive date of February 10, 2010.

What is the CFDA number associated with this award?

The associated CFDA number is 12.420 (Military Medical Research and Development).

Who administered the award?

The award was administered by USAMRAA under the Department of the Army.

Where could applicants get help or access the full announcement?

The announcement listed contact points for accessing the full announcement and for submission help through CDMRP assistance channels.

Are the designated military treatment facilities (MTFs) listed here?

No. The description notes that designated MTFs are referenced in the full announcement, but they are not listed in the information provided here.